What are the contraindications and adverse effects of tigecycline?

Tigecycline Adverse Effects and Contraindications

Tigecycline is contraindicated in patients with known hypersensitivity to tigecycline or any tetracycline-class antibiotic, during pregnancy and breastfeeding, and in children under 8 years of age due to risk of permanent tooth discoloration. 1

Absolute Contraindications

• Hypersensitivity: Known hypersensitivity to tigecycline or any tetracycline-class antibiotic, including anaphylactic reactions. 1
• Pregnancy (Category D): Tigecycline crosses the placenta and causes fetal harm in animal studies, including reduced fetal weights, skeletal anomalies (delayed bone ossification), and increased fetal loss at maternotoxic doses. Use only if potential benefit justifies fetal risk. 1, 2
• Breastfeeding: Tigecycline is excreted in breast milk (demonstrated in animal studies with 14C-labeled tigecycline). Caution is advised when administering to nursing women. 1, 2
• Children under 8 years: Contraindicated due to risk of permanent tooth discoloration, consistent with tetracycline-class effects. 1, 2, 3

Major Adverse Effects Requiring Monitoring

Increased Mortality Risk (Black Box Warning Consideration)

• Higher mortality rates observed in tigecycline-treated patients compared to comparators across clinical trials: adjusted mortality 2.5% versus 1.8% for comparators (adjusted risk difference 0.6%, 95% CI 0.0–1.2). 1
• Sepsis/septic shock occurred more frequently with tigecycline (2%) versus comparators (1%). 1, 3
• Infection-related serious adverse reactions were more common with tigecycline (7%) versus comparators (6%). 1

Gastrointestinal Effects (Most Common)

• Nausea: Occurs in 26% of patients (17% mild, 8% moderate, 1% severe); incidence varies by indication—35% in cSSSI, 25% in cIAI, 24% in CABP. 1, 4
• Vomiting: Occurs in 18% of patients (11% mild, 6% moderate, 1% severe); incidence 20% in cSSSI and cIAI, 16% in CABP. 1, 4
• Diarrhea: Reported in 11.6% of patients. 4
• Anorexia, abnormal stools: Occur in <2% of patients. 1
• Acute pancreatitis: Reported in post-marketing surveillance. 1

Management: Consider antiemetics and slower infusion rates; lower doses (50 mg/day instead of 50 mg twice daily) may improve tolerance. 3

Hepatic Effects

• Elevated liver function tests reported during therapy. 2, 3, 1
• Hepatic cholestasis and jaundice identified in post-marketing surveillance. 1
• Dose adjustment required: In severe hepatic impairment (Child-Pugh class C), reduce maintenance dose by 50% to 25 mg IV every 12 hours while retaining 100 mg loading dose. 2

Hematological Effects

• Prolonged prothrombin time (PT) and activated partial thromboplastin time (aPTT): Coagulation parameters must be monitored, especially in patients on warfarin. 2, 3, 1
• Prolonged INR: Reported in <2% of patients. 1
• Eosinophilia and thrombocytopenia: Occur in <2% of patients. 1

Metabolic Effects

• Hypoglycemia: Symptomatic hypoglycemia reported in patients with and without diabetes mellitus in post-marketing surveillance. 1, 3
• Hypoproteinemia, elevated amylase, elevated blood urea nitrogen: Observed during therapy. 3, 1
• Hypocalcemia: Reported in <2% of patients. 1

Dermatological Effects

• Rash: Occurs in 3% of patients. 3
• Pruritus: Occurs in <2% of patients. 3, 1
• Stevens-Johnson Syndrome: Severe skin reaction identified in post-marketing surveillance. 1

Neurological Effects

• Headache: Reported in 6% of patients. 3, 4
• Dizziness: Occurs in 3% of patients. 3
• Taste perversion: Reported in <2% of patients. 1

Vascular and Injection Site Effects

• Phlebitis: Occurs in 3% of patients. 3
• Thrombophlebitis: Reported in <2% of patients. 1
• Injection site reactions: Including inflammation, pain, edema, and phlebitis (collectively 8.2%). 1, 4

Genitourinary Effects

• Vaginal moniliasis, vaginitis, leukorrhea: Reported in <2% of patients. 1

Special Populations and Precautions

Pediatric Use (8–18 years)

• Not recommended for patients under 18 years due to increased mortality observed in adult trials; pediatric efficacy trials were not conducted. 1
• If no alternative exists: Ages 8–11 years: 1.2 mg/kg IV every 12 hours (maximum 50 mg per dose); Ages 12–18 years: adult dosing (100 mg loading, then 50 mg every 12 hours). 2

Renal Impairment

• No dose adjustment required for renal impairment or continuous renal replacement therapy. 2

Drug Interactions

• Warfarin: Monitor PT/INR or other suitable anticoagulation tests when co-administered. 1
• Oral contraceptives: Concurrent use may render oral contraceptives less effective. 1

Clinical Caveats

• Avoid monotherapy for bacteremia: Tigecycline achieves low serum concentrations (Cmax 0.87 mg/L with standard dosing) and is associated with poor outcomes in bloodstream infections. 2
• Not for pneumonia monotherapy: Low concentrations in endothelial lining fluid (0.01–0.02 mg/L) explain lower efficacy in VAP; combination therapy is essential. 2
• Discontinuation rates: Most frequently due to nausea (1%) and vomiting (1%). 1